Mélanie Mercier

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report

Mira Tout, Olivier Casasnovas, Michel Meignan et al. · Blood · 2017 · 89 citations · Full text

Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Amandine Fayard, Élisabeth Daguenet, Didier Blaise et al. · Bone Marrow Transplantation · 2019 · 49 citations · Full text

Transplantation, Marrow Transplantation, Infectious Complications +7

National survey of hepatitis B virus (HBV) polymorphism in asymptomatic HBV blood donors from 1999 to 2007 in France

Annabelle Servant‐Delmas, Mélanie Mercier, Marie‐Hélène El Ghouzzi et al. · Transfusion · 2010 · 36 citations

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

Justine Decroocq, Raphaël Itzykson, Stéphane Vigouroux et al. · American Journal of Hematology · 2017 · 28 citations · Full text

Cell Therapy, Similar Outcome, Immunology +18

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

Mira Tout, Anne-Laure Gagez, Stéphane Leprêtre et al. · Clinical Pharmacokinetics · 2016 · 27 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Target-mediated Elimination +13